Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study

Kai-Lin Huang: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Han-Ting Wei: Affiliation:
Department of Psychiatry, College of Medicine, National Yang-Ming University and Linsen Chinese Medicine and Kunming Branch, Taipei City Hospital, Taiwan
Ju-Wei Hsu*: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Ya-Mei Bai: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Tung-Ping Su: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital, Department of Psychiatry, College of Medicine, National Yang-Ming University and Department of Psychiatry, General Cheng Hsin Hospital, Taipei, Taiwan
Cheng-Ta Li: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Wei-Chen Lin: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Shih-Jen Tsai: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan
Wen-Han Chang: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
Tzeng-Ji Chen: Affiliation:
Department of Family Medicine, Taipei Veterans General Hospital and Institute of Hospital and Health Care Administration,National Yang-Ming University, Taipei, Taiwan
Mu-Hong Chen*: Affiliation:
Department of Psychiatry, Taipei Veterans General Hospital and Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan.
*: Correspondence: Mu-Hong Chen, MD, Department of Psychiatry, No. 201, Shih-Pai Road, Section 2, 11217, Taipei, Taiwan. Email: [email protected]
Correspondence: Mu-Hong Chen, MD, Department of Psychiatry, No. 201, Shih-Pai Road, Section 2, 11217, Taipei, Taiwan. Email: [email protected]

Article contents

Abstract
Background
Aims
Method
Results
Conclusion
Declaration of interest
Method
Results
Discussion
Footnotes
References

Rights & Permissions

Abstract

Background

Attention-deficit hyperactivity disorder (ADHD) increases the risk of suicidal behaviours through psychiatric comorbidities; however, a significant direct association has not been observed between ADHD and suicide attempts.

Aims

To evaluate the risk of suicide attempt in adolescents and young adults with ADHD.

Method

Using a nationwide, population-based insurance claims database, this longitudinal cohort study enrolled 20 574 adolescents and young adults with ADHD and 61 722 age- and gender-matched controls between 2001 and 2009. Any suicide attempt was identified from enrolment to 31 December 2011. The association between ADHD medications and the likelihood of suicide attempt was assessed.

Results

ADHD was an independent risk factor for any suicide attempt (hazard ratio = 3.84, 95% CI = 3.19–4.62) and repeated suicide attempts (hazard ratio = 6.52, 95% CI = 4.46–9.53). Subgroup analyses of men, women, adolescents and young adults demonstrated the same trend. Methylphenidate or atomoxetine treatment did not increase the risk of suicide attempt or repeated suicide attempts. Long-term methylphenidate treatment was associated with a significantly decreased risk of repeated suicide attempts in men (hazard ratio = 0.46, 95% CI = 0.22–0.97).

Conclusion

ADHD was a risk factor for suicide attempt and a stronger predictor of repeated suicide attempts, independent of comorbidities. Further investigation is warranted to explore the mechanism underlying the association between ADHD and suicidal behaviours.

Declaration of interest

None.

Type: Papers
Information: The British Journal of Psychiatry , Volume 212 , Issue 4 , April 2018 , pp. 234 - 238

DOI: https://doi.org/10.1192/bjp.2018.8 [Opens in a new window]
Copyright: Copyright © The Royal College of Psychiatrists 2018

Introduction of ADHD

Attention-deficit hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental disorder. Children are often diagnosed with ADHD during preschool years following symptoms such as frequent fidgeting or squirmy behaviours, inability to follow instructions and high distractibility. The prevalence of ADHD is estimated to be 5.29–7.1% in children and adolescents and 1.2–7.3% in adults.Reference Fayyad, De Graaf, Kessler, Alonso, Angermeyer and Demyttenaere¹^–Reference Willcutt³ The consequences of ADHD can persist through adulthood if left untreated or uncontrolled. A study suggested that ADHD is associated with an increased risk of various psychiatric disorders such as depression, antisocial behaviours, substance misuse, cognitive impairments and loss of inhibition.Reference Furczyk and Thome⁴ The associated comorbidities may not only exert a negative effect on person's life but also have correlations among each other.

ADHD and suicidality

One important concern is the association between ADHD and suicidal ideation, suicide attempts and suicidal behaviours. Studies have reported that ADHD combined with its comorbidities may be a risk factor for suicidal behaviours in children and adults; however, less is known about a significant direct relationship between ADHD and suicidal behaviors.Reference Agosti, Chen and Levin⁵^, Reference Taylor, Boden and Rucklidge⁶ A cohort study of 51 707 patients with ADHD concluded that ADHD increased the risk of suicide attempts and completed suicide even after adjustment for comorbidities.Reference Ljung, Chen, Lichtenstein and Larsson⁷ In addition, some evidence suggested a possible relationship between ADHD medications and suicide risk.Reference McCarthy, Cranswick, Potts, Taylor and Wong⁸ McCarthy et al Reference McCarthy, Cranswick, Potts, Taylor and Wong⁸ demonstrated an increase in the risk of death by suicide associated with ADHD medications. Suicide has become one of the leading causes of death in adolescents and young adults globally; therefore, further investigation is warranted to elucidate the direct association between ADHD and suicidal behaviours.

Study goal

Using randomised controlled trials to explore the occurrence of suicidal attempts in response to particular drug treatments or concomitant psychiatric disorders is often extremely challenging and controversial due to limited sample sizes, short study durations and strict inclusion criteria. Therefore, large population-based observational studies may be preferred to overcome these challenges. In this longitudinal cohort study, we used a nationwide, population-based insurance claims database with a large sample size and a longitudinal follow-up study design to evaluate the risk of suicide attempts in adolescents and young adults with ADHD.

Method

Data source

Taiwan's National Health Insurance, a mandatory universal health insurance program, was implemented in 1995 and offers comprehensive medical care coverage to all Taiwanese residents. The National Health Research Institutes (NHRI) manages the insurance claims database, i.e. the National Health Insurance Research Database (NHIRD), which consists of healthcare data from >99% of the Taiwan population. The NHRI audits and releases the NHIRD for scientific study purposes. Individual medical records included in the NHIRD are anonymously maintained to protect patient privacy. Comprehensive information on insured individuals – such as demographic data, clinical visit dates, disease diagnoses and medical interventions – is included in the database. The ICD-9 Clinical Modification (ICD-9-CM)⁹ codes are used for disease diagnosis. The NHIRD has been used extensively in many epidemiologic studies in Taiwan.Reference Chen, Lan, Hsu, Huang, Su and Li¹⁰^–Reference Wang, Chen, Tsai, Li, Luo and Wang¹³

Inclusion criteria for ADHD and control cohorts

Adolescents (aged 12–17 years) and young adults (aged 18–29 years) who received a diagnosis of ADHD (ICD-9-CM 314) by board-certified psychiatrists between 1 January 2001 and 31 December 2009 and did not have a history of suicide attempts before enrolment were included in the ADHD cohort (Table 1). The time of ADHD diagnosis was defined as the time of enrolment. An age-, gender- and enrolment time-matched (1:4) control cohort was randomly identified after eliminating the study individuals, those who received a diagnosis of ADHD at any time and those with a history of suicide attempts before enrolment. Any suicide attempt was identified during follow-up (from enrolment to 31 December 2011, or until death) and was defined by the codes for suicide attempts and non-accidental poisoning by drug and non-medical substances. The codes were given by board-certificated physicians. Psychiatric comorbidities – including disruptive behaviour disorders, unipolar depression, bipolar disorder, anxiety disorders, alcohol misuse disorders and substance misuse disorders – were diagnosed by board-certificated psychiatrists and assessed as the confounding factors in our study. In addition, the use of ADHD medications (methylphenidate or atomoxetine) during follow-up was examined, and the study population was divided into three subgroups accordingly: non-users (cumulative defined daily dose [cDDD] during follow-up <30), short-term users (cDDD = 30–364) and long-term users (cDDD ≥ 365). Furthermore, urbanisation levels (1–5; level 1: most urbanized region; level 5: least urbanized region) were assessed.Reference Liu, Hung, Chuang, Chen, Weng and Liu¹⁴

Table 1 Demographic data and incidence of suicide attempts among adolescents and young adults with ADHD and controls

ADHD, attention-deficit hyperactivity disorder; cDDD, cumulative defined daily dose; NTD, new Taiwan dollar.

The Taipei Veterans General Hospital institution review board approved this study.

Statistical analysis

For between-group comparisons, the independent t-test was used for continuous variables and the Pearson χ² test was used for nominal variables, where appropriate. Cox regression analyses were performed after adjustment for demographic data (age, gender, income and urbanisation levels), psychiatric comorbidities and ADHD medications to calculate hazard ratios, with a 95% confidence interval, of any suicide attempt or repeated (two or more) suicide attempts in the ADHD and control cohorts. Sensitivity analyses were performed to investigate the association between ADHD and any suicide attempt after excluding the first year or first 3 years of observation. In addition, we performed subgroup analyses on the risk of any suicide attempt in gender- and age-stratified ADHD groups: adolescents (<18 years old) and young adults (18–29 years old). A two-tailed P-value <0.05 was considered statistically significant. All data processing and statistical analyses were performed with SPSS version 17 software and Statistical Analysis Software (SAS) version 9.1 (SAS Institute, Cary, NC, USA).

Results

This study included 82 296 individuals: 20 574 in the ADHD cohort and 61 722 in the age- and gender-matched control cohort. The ADHD cohort had a mean age of 14.96 years, and 78.8% were men. The ADHD cohort received significantly longer methylphenidate and atomoxetine treatments, had more psychiatric comorbidities, lower income-related insurance amounts and a higher proportion of the cohort was living in rural areas in comparison with the control cohort (all P < 0.001). The incidences of any suicide attempt and repeated suicide attempts in the ADHD cohort were 2.7 and 0.8%, respectively, which were significantly higher than those in the control cohort (0.5 and 0.1%, respectively, both P < 0.001). The patients in the ADHD cohort were younger at their first suicide attempt (19.35 v. 20.77 years, P < 0.001) and had a shorter duration between study enrolment and their first suicide attempt (3.36 v. 5.10 years, P < 0.001) than the individuals in the control cohort (Table 1).

Kaplan–Meier survival analysis revealed that the ADHD cohort exhibited a significantly higher probability of any suicide attempt (P < 0.001; Fig. 1) than the control cohort. Cox regression analysis showed that ADHD was an independent risk factor for any suicide attempt (hazard ratio = 3.84, 95% CI = 3.19–4.62) and a stronger risk factor for repeated suicide attempts (hazard ratio = 6.52, 95% CI = 4.46–9.53). Furthermore, subgroup analyses of men, women, adolescents and young adults exhibited the same trend (Tables 2 and 3). After the observation data for the first year or first 3 years were excluded, sensitivity analysis consistently showed that ADHD was associated with a higher risk (hazard ratio = 2.76, 95% CI = 2.24–3.39 for adolescents; hazard ratio = 2.68, 95% CI = 2.10–3.43 for young adults) of any suicide attempt in adolescents and young adults (Supplementary Table S1, available at https://doi.org/10.1192/bjp.2018.8).

Fig. 1 Survival curve of developing any suicide attempt among adolescents and young adults with attention-deficit hyperactivity disorder (ADHD) and controls.

Table 2 Cox regression analyses of the risk of any suicide attempt among adolescents and young adults with attention-deficit hyperactivity disorder and controls

Cox regression analyses were performed after adjustment for demographic data, psychiatric comorbidities, and ADHD medications. Bold type indicates statistical significance. HR, hazard ratio; ADHD, attention-deficit hyperactivity disorder; cDDD: cumulative defined daily dose.

Table 3 Cox regression analyses of the risk of repeated suicide attempts among adolescents and young adults with attention-deficit hyperactivity disorder and controls

Both methylphenidate treatment and atomoxetine treatment were not significantly associated with the risk of any suicide attempt and repeated suicide attempts (Tables 2 and 3). Notably, the subgroup analyses revealed that long-term methylphenidate treatment was associated with a significantly decreased risk of repeated suicide attempts in men with ADHD (hazard ratio = 0.46, 95% CI = 0.22–0.97; Table 3).

Discussion

The results of this longitudinal cohort study revealed that ADHD was an independent and direct risk factor for any suicide attempt, and an even stronger risk factor for repeated suicide attempts. Methylphenidate or atomoxetine treatment did not increase the risk of suicide attempts or repeated suicide attempts. According to our review of the relevant literature, this study is the first to evaluate the risk of repeated suicide attempts in adolescents and young adults with ADHD.

The association between the risk of suicide attempts and ADHD has largely been thought to be due to the comorbidities of ADHD.Reference Furczyk and Thome⁴ James et al Reference James, Lai and Dahl¹⁵ reported that ADHD increases the risk of suicide attempts in men by increasing the severity of comorbidities, particularly depression and conduct disorders, and the direct relationship between ADHD and the risk of suicide attempts was modest. In the mediation model proposed by Taylor et al,Reference Taylor, Boden and Rucklidge⁶ the association between ADHD and the risk of suicide attempts in adults was mediated by comorbid mental health disorders; however, ADHD and suicide attempts did not have a statistically significant direct association. In contrast, our study demonstrated that ADHD significantly increased the risk of suicide attempts, independent of comorbidities. These results are comparable with those of a population-based study of 51 707 patients with ADHD by Ljung et al,Reference Ljung, Chen, Lichtenstein and Larsson⁷ who reported that patients with ADHD had a significantly higher risk of suicide attempts (odds ratio = 3.62, 95% CI = 3.29–3.98) and completed suicide (odds ratio = 5.91, 95% CI = 2.45–14.27) than matched controls after adjustment for comorbid psychiatric disorders. Similarly, Stickley et al Reference Stickley, Koyanagi, Ruchkin and Kamio¹⁶ concluded that ADHD is independently associated with lifetime suicide ideation (odds ratio = 2.22, 95% CI = 1.67–2.95) and lifetime suicide attempts (odds ratio = 1.62, 95% CI = 1.08–2.44) in adults after adjustment for gender, age, education, ethnicity, income, stressful life events, alcohol and drug dependence and comorbid conditions. The independent effect of ADHD in suicide attempt may be explained by impulsivity, a primary symptom of ADHD.Reference Dvorak, Lamis and Malone¹⁷^–Reference Wang, He, Yu, Qiu, Yang and Qiao¹⁹ Klonsky et al Reference Klonsky and May¹⁸ found that people who attempted suicide exhibited less premeditation (a diminished ability to think through the consequences of actions) than did people with suicidal ideation. Patros et al Reference Patros, Hudec, Alderson, Kasper, Davidson and Wingate²⁰ showed that impulsivity was related to suicidal ideation and attempted suicide among undergraduate students.

Discrepancies among the aforementioned studies can be explained by several factors. First, regarding the assessment of suicidal behaviours, most studies have relied on self- or parent-reported outcomes; therefore, different degrees of recall and report biases might have been introduced in these studies.Reference Agosti, Chen and Levin⁵^, Reference Stickley, Koyanagi, Ruchkin and Kamio¹⁶^, Reference Cho, Kim, Choi, Kim, Shin and Lee²¹^–Reference Hinshaw, Owens, Zalecki, Huggins, Montenegro-Nevado and Swanson²³ Second, regarding the hypothetical relationship between ADHD and suicidal behaviours, studies have proposed different construct models after adjusting for various confounding factors, leading to conflicting conclusions.Reference Taylor, Boden and Rucklidge⁶^, Reference Patros, Hudec, Alderson, Kasper, Davidson and Wingate²⁰ Although the exact association between ADHD and suicide attempts remains unclear, healthcare providers should be aware of the risk of suicide attempts in people with ADHD, with or without comorbidities.

The pharmacological management of ADHD mainly includes stimulants and non-stimulants, and considerable concern has been raised regarding drug safety. An observational cohort study over 18 637 patient years reported that stimulants and atomoxetine were associated with an increased risk of completed suicide.Reference McCarthy, Cranswick, Potts, Taylor and Wong⁸ Furthermore, drug treatment for ADHD may increase the risk of suicide attempts in addition to disorders. In contrast, recent studies have reported that atomoxetine was not significantly associated with the risk of suicide attempts.Reference Bangs, Wietecha, Wang, Buchanan and Kelsey²⁴^, Reference Chen, Sjolander, Runeson, D'Onofrio, Lichtenstein and Larsson²⁵ In a meta-analysis of 32 randomised controlled trials with a total of 7248 patients with ADHD, the frequency of combined suicidal behaviours or suicidal ideation of an adult atomoxetine group was similar to that of an adult placebo group (0.11 v. 0.12%, P = 0.96). Although a paediatric atomoxetine group had more frequent suicidal ideation than a paediatric placebo group, differences were not statistically significant (0.37 v. 0.07%, P = 0.42).Reference Bangs, Wietecha, Wang, Buchanan and Kelsey²⁴ Furthermore, a register-based longitudinal study (37 936 patients with ADHD over 150 721 person years of follow-up) investigated the association between drug treatment and the risk of suicide attempts and reported similar conclusions:Reference Chen, Sjolander, Runeson, D'Onofrio, Lichtenstein and Larsson²⁵ although drug treatment was associated with a significantly higher rate of suicide-related events at the population level, the association was reversed in within-patient comparisons. For non-stimulant or mixed users, within-patient rates of suicide-related events did not increase significantly during treatment periods (hazard ratio = 0.96, 95% CI = 0.72–1.30). Moreover, stimulant treatment provided beneficial effects and was associated with a reduced within-patient rate of suicide-related events during treatment periods (hazard ratio = 0.81, 95% CI = 0.70–0.94).Reference Chen, Sjolander, Runeson, D'Onofrio, Lichtenstein and Larsson²⁵ Our study confirmed the finding that long-term methylphenidate treatment is associated with a significantly decreased risk of repeated suicide attempts in men. In addition, both methylphenidate and atomoxetine treatment were not associated with a risk of any suicide attempt or repeated suicide attempts. Our results provide additional evidence on the safety concerns related to the pharmacological treatment of ADHD.

This study has several limitations. First, this was a secondary analysis study based on an insurance claims database. Several potentially confounding factors were unavailable, such as family history, personal lifestyles, disease severity and environmental factors. Second, this study focused only on suicide attempts because of the limitations of the insurance claims database. We did not analyse completed suicide or suicidal ideation. Third, the incidence of suicide attempts may be underestimated as a potential identification bias because only those who sought medical consultation and help would be included in the study. However, the suicide attempts were coded by board-certificated physicians, improving the validity. Further clinical studies will be required to re-confirm our findings. Fourth, the difference in age at first suicide attempt between ADHD patients and the controls was small but statistically significant, which may be due to such a large sample size. However, the younger age at first suicide attempt may indicate an earlier development of severe psychopathology, especially attempted suicide, among patients with ADHD compared with the controls. Fifth, in our study, the cDDD of ADHD medications indicated the duration and the cumulative dosage of ADHD medications. The greater cDDD meant a longer period and higher dose of ADHD medication use. There was no information regarding management of patients beyond the number of days they were on the medications. So it may not be possible to know the level of control or effect the patient obtained from treatment. Further clinical study would be necessary to re-confirm our findings.

Our findings may inform clinicians and governmental public health providers of the crucial role of ADHD in the risk of suicidal behaviours and we suggest that optimal interventions for ADHD may reduce the risk of suicide attempts. Further investigation is warranted to explore the mechanism underlying the association between ADHD and suicidal behaviours.

Funding

The study was supported by grants from Taipei Veterans General Hospital (V103E10-001, V104E10-002, V105E10-001-MY2-1, V105A-049, V106B-020, V107B-010 and V107C-181). The funding source had no role in any process of our study.

Acknowledgements

We thank Mr I-Fan Hu for his friendship and support. We thank M.-H.C., H.-T.W., J.-W.H. and K.-L.H. who designed the study, wrote the protocol and manuscripts; T.-P.S., C.-T.L., S.-J.T., Y.-M.B. and W.-C.L. who assisted with the preparation and proofreading of the manuscript; and Y.-M.B., T.-J.C. and W.-H.C. who provided the advices on statistical analysis.

Supplementary material

Supplementary material is available online at https://doi.org/10.1192/bjp.2018.8.

Footnotes

These authors contributed equally to this article.

References

1Fayyad, J, De Graaf, R, Kessler, R, Alonso, J, Angermeyer, M, Demyttenaere, K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402–9.Google Scholar

2Polanczyk, G, de Lima, MS, Horta, BL, Biederman, J, Rohde, LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942–8.Google Scholar

3Willcutt, EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9: 490–9.Google Scholar

4Furczyk, K, Thome, J. Adult ADHD and suicide. Atten Defic Hyperact Disord 2014; 6: 153–8.Google Scholar

5Agosti, V, Chen, Y, Levin, FR. Does attention deficit hyperactivity disorder increase the risk of suicide attempts? J Affect Disord 2011; 133: 595–9.Google Scholar

6Taylor, MR, Boden, JM, Rucklidge, JJ. The relationship between ADHD symptomatology and self-harm, suicidal ideation, and suicidal behaviours in adults: a pilot study. Atten Defic Hyperact Disord 2014; 6: 303–12.Google Scholar

7Ljung, T, Chen, Q, Lichtenstein, P, Larsson, H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. JAMA Psychiatry 2014; 71: 958–64.Google Scholar

8McCarthy, S, Cranswick, N, Potts, L, Taylor, E, Wong, IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety 2009; 32: 1089–96.Google Scholar

9Medicode (Firm). ICD-9-CM: International classification of diseases, 9th revision, clinical modification. Medicode, 2014.Google Scholar

10Chen, MH, Lan, WH, Hsu, JW, Huang, KL, Su, TP, Li, CT, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study. Diabetes Care 2016; 39: 788–93.Google Scholar

11Chen, MH, Pan, TL, Li, CT, Lin, WC, Chen, YS, Lee, YC, et al. Risk of stroke among patients with post-traumatic stress disorder: nationwide longitudinal study. Br J Psychiatry 2015; 206: 302–7.Google Scholar

12Li, CT, Bai, YM, Huang, YL, Chen, YS, Chen, TJ, Cheng, JY, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 2012; 200: 45–51.Google Scholar

13Wang, YP, Chen, YT, Tsai, CF, Li, SY, Luo, JC, Wang, SJ, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171: 54–61.Google Scholar

14Liu, C-Y, Hung, Y-T, Chuang, Y-L, Chen, YJ, Weng, WS, Liu, JS. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006; 4: 1–22.Google Scholar

15James, A, Lai, FH, Dahl, C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004; 110: 408–15.Google Scholar

16Stickley, A, Koyanagi, A, Ruchkin, V, Kamio, Y. Attention-deficit/hyperactivity disorder symptoms and suicide ideation and attempts: findings from the Adult Psychiatric Morbidity Survey 2007. J Affect Disord 2016; 189: 321–8.Google Scholar

17Dvorak, RD, Lamis, DA, Malone, PS. Alcohol use, depressive symptoms, and impulsivity as risk factors for suicide proneness among college students. J Affect Disord 2013; 149: 326–34.Google Scholar

18Klonsky, ED, May, A. Rethinking impulsivity in suicide. Suicide Life Threat Behav 2010; 40: 612–9.Google Scholar

19Wang, L, He, CZ, Yu, YM, Qiu, XH, Yang, XX, Qiao, ZX, et al. Associations between impulsivity, aggression, and suicide in Chinese college students. BMC Public Health 2014; 14: 551.Google Scholar

20Patros, CH, Hudec, KL, Alderson, RM, Kasper, LJ, Davidson, C, Wingate, LR. Symptoms of attention-deficit/hyperactivity disorder (ADHD) moderate suicidal behaviors in college students with depressed mood. J Clin Psychol 2013; 69: 980–93.Google Scholar

21Cho, SC, Kim, JW, Choi, HJ, Kim, BN, Shin, MS, Lee, JH, et al. Associations between symptoms of attention deficit hyperactivity disorder, depression, and suicide in Korean female adolescents. Depress Anxiety 2008; 25: E142–6.Google Scholar

22Chronis-Tuscano, A, Molina, BS, Pelham, WE, Applegate, B, Dahlke, A, Overmyer, M, et al. Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2010; 67: 1044–51.Google Scholar

23Hinshaw, SP, Owens, EB, Zalecki, C, Huggins, SP, Montenegro-Nevado, AJ, Swanson, EN, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol 2012; 80: 1041–51.Google Scholar

24Bangs, ME, Wietecha, LA, Wang, S, Buchanan, AS, Kelsey, DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014; 24: 426–34.Google Scholar

25Chen, Q, Sjolander, A, Runeson, B, D'Onofrio, BM, Lichtenstein, P, Larsson, H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348: g3769.Google Scholar

Table 1 Demographic data and incidence of suicide attempts among adolescents and young adults with ADHD and controls

Fig. 1 Survival curve of developing any suicide attempt among adolescents and young adults with attention-deficit hyperactivity disorder (ADHD) and controls.

Table 2 Cox regression analyses of the risk of any suicide attempt among adolescents and young adults with attention-deficit hyperactivity disorder and controls

Table 3 Cox regression analyses of the risk of repeated suicide attempts among adolescents and young adults with attention-deficit hyperactivity disorder and controls

Huang et al. supplementary material

Table S1

File 29.2 KB

Submit a response

eLetters

No eLetters have been published for this article.

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Krinzinger, Helga Hall, Charlotte L Groom, Madeleine J Ansari, Mohammed T Banaschewski, Tobias Buitelaar, Jan K Carucci, Sara Coghill, David Danckaerts, Marina Dittmann, Ralf W Falissard, Bruno Garas, Peter Inglis, Sarah K Kovshoff, Hanna Kochhar, Puja McCarthy, Suzanne Nagy, Peter Neubert, Antje Roberts, Samantha Sayal, Kapil Sonuga-Barke, Edmund Wong, Ian C K Xia, Jun Zuddas, Alessandro Hollis, Chris Konrad, Kerstin and Liddle, Elizabeth B 2019. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neuroscience & Biobehavioral Reviews, Vol. 107, Issue. , p. 945.

Chang, Zheng Ghirardi, Laura Quinn, Patrick D. Asherson, Philip D’Onofrio, Brian M. and Larsson, Henrik 2019. Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases. Biological Psychiatry, Vol. 86, Issue. 5, p. 335.

Baraskewich, Jessica and McMorris, Carly A. 2019. Internalizing Mental Health Issues in Individuals with Neurodevelopmental Disorders: Implications for Practitioners. Current Developmental Disorders Reports, Vol. 6, Issue. 1, p. 1.

Chen, Mu-Hong Huang, Kai-Lin Hsu, Ju-Wei and Tsai, Shih-Jen 2019. Treatment-resistant attention-deficit hyperactivity disorder: Clinical significance, concept, and management. Taiwanese Journal of Psychiatry, Vol. 33, Issue. 2, p. 66.

He, Guan-Hao Strodl, Esben Liu, Li Ruan, Zeng-Liang Yin, Xiao-Na Wen, Guo-Ming Sun, Deng-Li Xian, Dan-Xia Jiang, Hui Jing, Jin Jin, Yu Wu, Chuan-An and Chen, Wei-Qing 2019. Teacher’s Type D Personality and Chinese Children’s Hyperactive Behaviors: Moderation Effect of Parental Type D Personality and Mediation Effect of Teacher–Student Relationship. Frontiers in Psychology, Vol. 10, Issue. ,

Guo, Lan Wang, Wanxin Wang, Tian Li, Wenyan Gong, Meiqian Zhang, Sheng Zhang, Wei-Hong and Lu, Ciyong 2019. Association of emotional and behavioral problems with single and multiple suicide attempts among Chinese adolescents: Modulated by academic performance. Journal of Affective Disorders, Vol. 258, Issue. , p. 25.

Faraone, Stephen V. 2020. The Impact of Attention-Deficit/Hyperactivity Disorder Medications on Suicidality: Implications and Mechanisms. Biological Psychiatry, Vol. 88, Issue. 6, p. 436.

Protti, Michele Mandrioli, Roberto Marasca, Camilla Cavalli, Andrea Serretti, Alessandro and Mercolini, Laura 2020. New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Medicinal Research Reviews, Vol. 40, Issue. 5, p. 1794.

Öhlund, Louise Ott, Michael Lundqvist, Robert Sandlund, Mikael Salander Renberg, Ellinor and Werneke, Ursula 2020. Suicidal and non-suicidal self-injurious behaviour in patients with bipolar disorder and comorbid attention deficit hyperactivity disorder after initiation of central stimulant treatment: a mirror-image study based on the LiSIE retrospective cohort. Therapeutic Advances in Psychopharmacology, Vol. 10, Issue. ,

Siffel, Csaba DerSarkissian, Maral Kponee-Shovein, Kalé Spalding, William Gu, Yuqian M. Cheng, Mu and Duh, Mei S. 2020. Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit/hyperactivity disorder. Journal of Affective Disorders, Vol. 266, Issue. , p. 109.

Chou, Wen-Jiun Liu, Tai-Ling Hsiao, Ray C. Chen, Yu-Min Chang, Chih-Cheng and Yen, Cheng-Fang 2020. Application and Perceived Effectiveness of Complementary and Alternative Intervention Strategies for Attention-Deficit/Hyperactivity Disorder: Relationships with Affiliate Stigma. International Journal of Environmental Research and Public Health, Vol. 17, Issue. 5, p. 1505.

Boland, Heidi DiSalvo, Maura Fried, Ronna Woodworth, K. Yvonne Wilens, Timothy Faraone, Stephen V. and Biederman, Joseph 2020. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of Psychiatric Research, Vol. 123, Issue. , p. 21.

Garas, Peter and Balazs, Judit 2020. Long-Term Suicide Risk of Children and Adolescents With Attention Deficit and Hyperactivity Disorder—A Systematic Review. Frontiers in Psychiatry, Vol. 11, Issue. ,

Rukundo, Godfrey Zari Mpango, Richard Stephen Ssembajjwe, Wilber Gadow, Kenneth D. Patel, Vikram and Kinyanda, Eugene 2020. Prevalence and risk factors for youth suicidality among perinatally infected youths living with HIV/AIDS in Uganda: the CHAKA study. Child and Adolescent Psychiatry and Mental Health, Vol. 14, Issue. 1,

Chen, Yi-Lung Ho, Hsing-Ying Hsiao, Ray C. Lu, Wei-Hsin and Yen, Cheng-Fang 2020. Correlations between Quality of Life, School Bullying, and Suicide in Adolescents with Attention-Deficit Hyperactivity Disorder. International Journal of Environmental Research and Public Health, Vol. 17, Issue. 9, p. 3262.

Liu, Wen‐juan Mao, Hong‐jing Hu, Lin‐lin Song, Ming‐fen Jiang, Hai‐yin and Zhang, Lei 2020. Attention‐deficit/hyperactivity disorder medication and risk of suicide attempt: A meta‐analysis of observational studies. Pharmacoepidemiology and Drug Safety, Vol. 29, Issue. 11, p. 1364.

Gao, Le Man, Kenneth K. C. Chan, Esther W. Chui, Celine S. L. Li, Xue Coghill, David Hon, Kam Lun Tse, Man Li Lum, Terry Y. S. Wong, Kirstie H. T. W. Ip, Patrick and Wong, Ian C. K. 2021. Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study. CNS Drugs, Vol. 35, Issue. 7, p. 769.

Faraone, Stephen V. Banaschewski, Tobias Coghill, David Zheng, Yi Biederman, Joseph Bellgrove, Mark A. Newcorn, Jeffrey H. Gignac, Martin Al Saud, Nouf M. Manor, Iris Rohde, Luis Augusto Yang, Li Cortese, Samuele Almagor, Doron Stein, Mark A. Albatti, Turki H. Aljoudi, Haya F. Alqahtani, Mohammed M.J. Asherson, Philip Atwoli, Lukoye Bölte, Sven Buitelaar, Jan K. Crunelle, Cleo L. Daley, David Dalsgaard, Søren Döpfner, Manfred Espinet (on behalf of CADDRA), Stacey Fitzgerald, Michael Franke, Barbara Gerlach, Manfred Haavik, Jan Hartman, Catharina A. Hartung, Cynthia M. Hinshaw, Stephen P. Hoekstra, Pieter J. Hollis, Chris Kollins, Scott H. Sandra Kooij, J.J. Kuntsi, Jonna Larsson, Henrik Li, Tingyu Liu, Jing Merzon, Eugene Mattingly, Gregory Mattos, Paulo McCarthy, Suzanne Mikami, Amori Yee Molina, Brooke S.G. Nigg, Joel T. Purper-Ouakil, Diane Omigbodun, Olayinka O. Polanczyk, Guilherme V. Pollak, Yehuda Poulton, Alison S. Rajkumar, Ravi Philip Reding, Andrew Reif, Andreas Rubia, Katya Rucklidge, Julia Romanos, Marcel Ramos-Quiroga, J. Antoni Schellekens, Arnt Scheres, Anouk Schoeman, Renata Schweitzer, Julie B. Shah, Henal Solanto, Mary V. Sonuga-Barke, Edmund Soutullo, César Steinhausen, Hans-Christoph Swanson, James M. Thapar, Anita Tripp, Gail van de Glind, Geurt van den Brink, Wim Van der Oord, Saskia Venter, Andre Vitiello, Benedetto Walitza, Susanne and Wang, Yufeng 2021. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, Vol. 128, Issue. , p. 789.

Forte, Alberto Sarubbi, Salvatore Orri, Massimiliano Erbuto, Denise and Pompili, Maurizio 2021. ADHD symptoms and suicide attempts in adults with mood disorders: An observational naturalistic study. Journal of Affective Disorders Reports, Vol. 6, Issue. , p. 100224.

Arsandaux, Julie Orri, Massimiliano Tournier, Marie Gbessemehlan, Antoine Coté, Sylvana Salamon, Réda Tzourio, Christophe and Galéra, Cédric 2021. Pathways From ADHD Symptoms to Suicidal Ideation During College Years: A Longitudinal Study on the i-Share Cohort. Journal of Attention Disorders, Vol. 25, Issue. 11, p. 1534.

Download full list

Article contents

Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study

Abstract

Introduction of ADHD

ADHD and suicidality

Study goal

Method

Data source

Inclusion criteria for ADHD and control cohorts

Statistical analysis

Results

Discussion

Funding

Acknowledgements

Supplementary material

Footnotes

References

Huang et al. supplementary material

eLetters

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests